Your browser is no longer supported. Please, upgrade your browser.
Settings
DNAY [NASD]
Codex DNA, Inc.
Index- P/E- EPS (ttm)- Insider Own29.00% Shs Outstand29.29M Perf Week-8.90%
Market Cap281.92M Forward P/E- EPS next Y-1.33 Insider Trans0.00% Shs Float13.86M Perf Month-6.65%
Income- PEG- EPS next Q-0.28 Inst Own55.40% Short Float3.53% Perf Quarter-43.18%
Sales8.75M P/S32.22 EPS this Y-116.90% Inst Trans0.02% Short Ratio4.36 Perf Half Y-
Book/sh3.84 P/B2.56 EPS next Y0.70% ROA- Target Price- Perf Year-
Cash/sh4.32 P/C2.28 EPS next 5Y- ROE- 52W Range9.53 - 25.70 Perf YTD-46.86%
Dividend- P/FCF- EPS past 5Y- ROI79.40% 52W High-61.52% Beta-
Dividend %- Quick Ratio18.50 Sales past 5Y- Gross Margin- 52W Low3.78% ATR0.87
Employees108 Current Ratio18.70 Sales Q/Q76.40% Oper. Margin- RSI (14)36.94 Volatility6.11% 7.58%
OptionableNo Debt/Eq0.13 EPS Q/Q- Profit Margin- Rel Volume0.40 Prev Close9.83
ShortableYes LT Debt/Eq0.13 EarningsAug 10 AMC Payout- Avg Volume112.02K Price9.89
Recom1.70 SMA20-9.19% SMA50-17.31% SMA200-30.11% Volume44,971 Change0.61%
Oct-15-21Resumed Cowen Outperform
Jul-13-21Initiated KeyBanc Capital Markets Overweight $30
Jul-13-21Initiated Jefferies Buy $23
Jul-13-21Initiated Cowen Outperform
Aug-11-21 03:01AM  
Aug-10-21 04:15PM  
Aug-05-21 07:00AM  
Aug-03-21 07:00AM  
Jul-19-21 10:35AM  
Jun-22-21 04:10PM  
Jun-18-21 05:19PM  
Jun-17-21 10:16PM  
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.